EA030252B9 - Варианты полипептидов ph20, композиции на их основе и их применение - Google Patents

Варианты полипептидов ph20, композиции на их основе и их применение

Info

Publication number
EA030252B9
EA030252B9 EA201400772A EA201400772A EA030252B9 EA 030252 B9 EA030252 B9 EA 030252B9 EA 201400772 A EA201400772 A EA 201400772A EA 201400772 A EA201400772 A EA 201400772A EA 030252 B9 EA030252 B9 EA 030252B9
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptides
compositions
variants
basis
application
Prior art date
Application number
EA201400772A
Other languages
English (en)
Russian (ru)
Other versions
EA201400772A1 (ru
EA030252B1 (ru
Inventor
Ги Вей
Х. Майкл Шепард
Кипинг Цхао
Роберт Джеймс Коннор
Original Assignee
Галозим, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47595052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA030252(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Галозим, Инк. filed Critical Галозим, Инк.
Publication of EA201400772A1 publication Critical patent/EA201400772A1/ru
Publication of EA030252B1 publication Critical patent/EA030252B1/ru
Publication of EA030252B9 publication Critical patent/EA030252B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/926—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha -1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/926—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha -1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
    • G01N2333/928—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha -1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase acting on alpha -1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
EA201400772A 2011-12-30 2012-12-28 Варианты полипептидов ph20, композиции на их основе и их применение EA030252B9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161631313P 2011-12-30 2011-12-30
US201261796208P 2012-11-01 2012-11-01
PCT/US2012/072182 WO2013102144A2 (en) 2011-12-30 2012-12-28 Ph20 polypeptede variants, formulations and uses thereof

Publications (3)

Publication Number Publication Date
EA201400772A1 EA201400772A1 (ru) 2015-07-30
EA030252B1 EA030252B1 (ru) 2018-07-31
EA030252B9 true EA030252B9 (ru) 2021-09-08

Family

ID=47595052

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400772A EA030252B9 (ru) 2011-12-30 2012-12-28 Варианты полипептидов ph20, композиции на их основе и их применение

Country Status (23)

Country Link
US (29) US9447401B2 (enExample)
EP (2) EP2797622B1 (enExample)
JP (2) JP6067746B2 (enExample)
CN (1) CN104244968B (enExample)
AU (2) AU2012362141B2 (enExample)
BR (1) BR112014016195A2 (enExample)
CA (1) CA2861919C (enExample)
CY (1) CY1122532T1 (enExample)
DK (2) DK2797622T3 (enExample)
EA (1) EA030252B9 (enExample)
ES (2) ES2609582T3 (enExample)
HR (1) HRP20192249T1 (enExample)
HU (1) HUE047849T2 (enExample)
IL (5) IL298330B1 (enExample)
LT (1) LT3130347T (enExample)
MX (2) MX361727B (enExample)
PL (1) PL3130347T3 (enExample)
PT (1) PT3130347T (enExample)
RS (1) RS59703B1 (enExample)
SG (2) SG11201403714TA (enExample)
SI (1) SI3130347T1 (enExample)
SM (1) SMT201900630T1 (enExample)
WO (1) WO2013102144A2 (enExample)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
WO2009128917A2 (en) 2008-04-14 2009-10-22 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
CN102307993B (zh) * 2008-12-09 2014-06-25 哈洛齐梅公司 延长的可溶性ph20多肽及其用途
PT2477603E (pt) 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
DK2595624T3 (en) 2010-07-20 2018-03-26 Halozyme Inc Methods of treating or preventing adverse side effects associated with administration of an anti-hyaluronan agent
EP2720712B1 (en) * 2011-06-17 2016-03-02 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
CA2853358A1 (en) 2011-10-24 2013-05-02 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
SG11201403714TA (en) 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
EP2833905B1 (en) 2012-04-04 2018-05-02 Halozyme, Inc. Combination therapy with hyaluronidase and a tumor-targeted taxane
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
TW201534726A (zh) * 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
HUP1300646A2 (en) * 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN103819578B (zh) * 2013-11-22 2016-05-11 青岛九龙生物医药有限公司 一种加氢氧化钠法提高硫酸软骨素收率的方法
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US20150328317A1 (en) * 2014-05-13 2015-11-19 Eagle Pharmaceuticals, Inc. Aqueous buffer-free bivalirudin compositions
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
CN105727267B (zh) * 2016-02-05 2020-05-26 苏州康聚生物科技有限公司 一种重组人透明质酸酶冻干制剂及其制备方法和应用
GB201607918D0 (en) * 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
WO2017201635A1 (zh) * 2016-05-23 2017-11-30 蔡胜和 透明质酸酶的细胞表达及其在实体瘤细胞治疗中的应用
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
US10685790B2 (en) * 2016-06-29 2020-06-16 Innocell Aps Supercapacitor and a method for expanding the voltage range of an aqueous electrolyte suprcapacitor
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
EP4265296A3 (en) 2016-09-29 2023-12-20 Arecor Limited Pharmaceutical formulation comprising an insulin compound
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
CA3065308C (en) 2017-06-01 2022-05-17 Eli Lilly And Company Rapid-acting insulin compositions
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CN109913422A (zh) * 2017-12-13 2019-06-21 苏州康聚生物科技有限公司 一种包含肿瘤抗原识别受体的免疫细胞及其应用
EP3773474B1 (en) 2018-04-04 2026-01-07 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
MX2020009824A (es) * 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
CN112203642B (zh) * 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
UY38744A (es) 2019-06-07 2020-12-31 Nestle Skin Health S A Tratamiento de líneas glabelares y líneas cantales laterales de moderadas a muy graves
TW202615652A (zh) * 2020-01-23 2026-04-16 南韓商阿特根公司 新穎的具有改善的穩定性的玻尿酸酶變異體及含有其的醫藥組合物
CN111233979B (zh) * 2020-02-19 2026-04-03 四川大学华西医院 一种双子型两亲性短肽及其作为疏水性药物载体的应用
TWI881239B (zh) * 2020-06-09 2025-04-21 南韓商阿特根公司 用於皮下注射之包含人類玻尿酸酶ph20變異體及藥物的醫藥組合物
TWI788188B (zh) * 2020-06-09 2022-12-21 南韓商阿特根公司 用於皮下注射之包含人類玻尿酸酶ph20變異體及藥物的醫藥組合物
TWI781415B (zh) * 2020-06-09 2022-10-21 南韓商阿特根公司 用於皮下注射之包含人類玻尿酸酶ph20變異體及藥物的醫藥組合物
CA3181682A1 (en) * 2020-07-17 2022-01-20 Anil Kapur Subcutaneous telomerase inhibitor compositions and methods for using same
WO2022031093A1 (ko) 2020-08-07 2022-02-10 (주)알테오젠 재조합 히알루로니다제의 생산 방법
KR20230069956A (ko) 2020-09-14 2023-05-19 베링거 인겔하임 인터내셔날 게엠베하 이종 프라임 부스트 백신
PT4267105T (pt) 2020-12-28 2025-04-30 Bristol Myers Squibb Co Composições de anticorpos e métodos de utilização das mesmas
CN112763610B (zh) * 2020-12-28 2022-04-01 浙江大学 土壤中抗生素的检测方法
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
CN112359027B (zh) 2021-01-13 2021-04-13 凯莱英生命科学技术(天津)有限公司 细胞色素p450酶突变体及其应用
CN114350691B (zh) * 2021-03-05 2023-12-08 华熙生物科技股份有限公司 一种高效表达透明质酸水解酶的基因及其表达方法
CN113444708B (zh) * 2021-07-19 2024-02-13 河南赛培生物科技有限公司 一种用于药物皮下注射制剂的透明质酸酶突变体
CN115671267A (zh) * 2021-07-23 2023-02-03 上海宝济药业有限公司 一种皮下抗生素药物组合物
WO2023012515A2 (en) 2021-08-02 2023-02-09 argenx BV Subcutaneous unit dosage forms
WO2023042096A1 (en) 2021-09-14 2023-03-23 Takeda Pharmaceutical Company Limited Facilitated delivery of concentrated antibody formulations using hyaluronidase
EP4419663A1 (en) * 2021-10-19 2024-08-28 Pharmact Holding AG A production of a purified modified bacterial hyaluronidase polypeptide, pharmaceutical compositions and their uses
CA3236277A1 (en) * 2021-10-29 2023-05-04 Soon Jae Park Pharmaceutical composition comprising human hyaluronidase ph20 and drug
CN116410956A (zh) * 2022-01-10 2023-07-11 上海宝济药业有限公司 一种新型透明质酸降解酶
CN114634920B (zh) * 2022-03-24 2024-02-27 江南大学 一种产人源透明质酸酶ph20的重组毕赤酵母及其构建方法
CN114624366B (zh) * 2022-05-16 2022-07-26 南京瑞克卫生物医药有限公司 一种醋酸西曲瑞克聚合物杂质的检测方法
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
KR102774438B1 (ko) * 2022-06-08 2025-02-27 (주)한국비엠아이 히알루로니다제 폴리펩티드 및 이의 용도
KR20250134732A (ko) 2022-12-22 2025-09-11 할로자임, 아이엔씨 대용량 투여를 위한 히알루로니다아제 효소 제형
CN116004581A (zh) * 2023-01-17 2023-04-25 武汉启瑞药业有限公司 一种高活性的透明质酸酶突变体及其制备寡聚透明质酸盐的应用
WO2024189048A1 (en) 2023-03-13 2024-09-19 Heidelberg Pharma Research Gmbh Subcutaneously administered antibody-drug conjugates for use in cancer treatment
CN116272708B (zh) * 2023-03-16 2023-11-14 海南医学院 一种量子点-抗体复合物微球及其制备方法、应用
WO2025158277A1 (en) 2024-01-22 2025-07-31 Janssen Biotech, Inc. Use of amivantamab to treat head and neck cancer
EP4740956A1 (en) 2024-02-08 2026-05-13 Shanghai Bao Pharmaceuticals Co., Ltd. Pharmaceutical combination for subcutaneous administration and use thereof
WO2025188901A1 (en) 2024-03-05 2025-09-12 Halozyme, Inc. Combination therapy with antibody-drug conjugates and hyaluronidases
WO2025191459A1 (en) 2024-03-11 2025-09-18 Janssen Biotech, Inc. Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
TW202615468A (zh) 2024-05-29 2026-04-16 美商健生生物科技公司 局部晚期或轉移性ｅｇｆｒ突變之非小細胞肺癌之治療
TW202617771A (zh) 2024-06-21 2026-05-01 美商艾普吉醫療股份有限公司 結合ｉｌ－１３之抗體及結合ｏｘ４０ｌ之抗體
WO2025264972A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-4r alpha and antibodies that bind
WO2026001707A1 (zh) * 2024-06-27 2026-01-02 上海复宏汉霖生物技术股份有限公司 一种新型透明质酸酶变体
WO2026022739A1 (en) 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026022733A1 (en) 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026054363A1 (ko) * 2024-09-05 2026-03-12 주식회사 휴온스랩 인플릭시맵 및 히알루로니다제를 포함하는 피하투여용 약제학적 제제
WO2026085415A1 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind tslp in combination with hyaluronidase or a variant thereof
WO2026085417A2 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof
WO2026085419A2 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind il-13 in combination with hyaluronidase or a variant thereof
WO2026085414A1 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind tslp and antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof
WO2026120486A1 (en) 2024-12-02 2026-06-11 Halozyme, Inc. Soluble hyaluronidase and production thereof
WO2026152008A1 (en) 2025-01-10 2026-07-16 Oric Pharmaceuticals, Inc. Enozertinib for treating epidermal growth factor receptor (egfr) exon 20 mutant nsclc in combination with amivantamab
WO2026163248A1 (en) * 2025-01-31 2026-08-06 Biocon Biologics Limited Recombinant human hyaluronidase polypeptide variants, method of preparation and pharmaceutical compositions thereof
CN120400103B (zh) * 2025-04-25 2026-02-03 上海齐鲁制药研究中心有限公司 新型ph20突变体酶
KR102943813B1 (ko) * 2025-05-09 2026-03-27 주식회사 진켐 효소 활성이 증가한 신규 히알루로니다제 ph20 변이체
KR102943811B1 (ko) * 2025-05-09 2026-03-27 주식회사 진켐 효소 활성과 발현이 증가한 신규 히알루로니다제 ph20 변이체
EP4756019A2 (en) 2025-06-19 2026-06-10 Qilu Pharmaceutical Co., Ltd. A composition comprising recombinant human hyaluronidase and variants thereof, and related methods and uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009128917A2 (en) * 2008-04-14 2009-10-22 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
US20100143457A1 (en) * 2008-12-09 2010-06-10 Ge Wei Extended soluble PH20 polypeptides and uses thereof
WO2012136768A1 (en) * 2011-04-08 2012-10-11 Hans-Dieter Haubeck Use of mutants of human hyaluronidase ph-20 with increased chondroitinase activity for axonal regrowth

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE3173600D1 (en) 1980-05-20 1986-03-13 Mallinckrodt Inc Spray dried n-acetyl-p-aminophenol compositions and method for manufacture thereof
AU546785B2 (en) * 1980-07-23 1985-09-19 Commonwealth Of Australia, The Open-loop controlled infusion of diabetics
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DK0400472T3 (da) 1989-05-27 1996-05-13 Sumitomo Pharma Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
CA2106301C (en) 1991-03-18 1999-04-06 Chi-Huey Wong Oligosaccharide enzyme substrates and inhibitors: method and compositions
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5795569A (en) 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
EE9600121A (et) 1994-03-31 1997-04-15 Amgen Inc. Megakarüotsüütide kasvu ja diferentseerumist stimuleerivad kompositsioonid ja meetodid
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US20010055563A1 (en) 1999-09-09 2001-12-27 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US5958750A (en) 1996-07-03 1999-09-28 Inctye Pharmaceuticals, Inc. Human hyaluronidase
US6461863B1 (en) 1996-08-16 2002-10-08 University Of Wyoming Modifying insect cell gylcosylation pathways with baculovirus expression vectors
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6193963B1 (en) 1996-10-17 2001-02-27 The Regents Of The University Of California Method of treating tumor-bearing patients with human plasma hyaluronidase
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
GB9803751D0 (en) 1998-02-23 1998-04-15 Smithkline Beecham Plc Novel compounds
CA2323048C (en) 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
WO2000002017A2 (en) 1998-07-03 2000-01-13 Neles Field Controls Oy Method and arrangement for measuring fluid
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
US6461802B1 (en) 1999-08-02 2002-10-08 Agfa-Gevaert Adhesive layer for polyester film
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
US6615063B1 (en) * 2000-11-27 2003-09-02 The General Hospital Corporation Fluorescence-mediated molecular tomography
EP1345628B1 (en) 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Conjugates of erythropoietin (epo) with polyethylene glycol (peg)
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
KR20040040782A (ko) 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
EP1596887B1 (en) 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
EP3211084B1 (en) * 2003-05-16 2019-03-27 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
PT2644206T (pt) 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
US20050054048A1 (en) 2003-07-29 2005-03-10 Luigi Grasso Antibodies and methods for generating genetically altered antibodies with enhanced effector function
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US20070067855A1 (en) 2003-10-28 2007-03-22 Chesapeake Perl, Inc. Production of human glycosylated proteins in transgenic insects
DE602004027291D1 (de) 2003-11-25 2010-07-01 Us Gov Health & Human Serv Mutierte anti-cd22-antikörper und immunkonjugate
EP2106790B1 (en) 2004-03-12 2012-10-24 Biodel, Inc. Rapid acting drug delivery compositions
US7112687B2 (en) 2004-07-15 2006-09-26 Indena, S.P.A. Methods for obtaining paclitaxel from taxus plants
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
JP5201572B2 (ja) 2005-06-09 2013-06-05 ナノキャリア株式会社 白金錯体のポリマー化配位化合物の製造方法
JP2007153797A (ja) 2005-12-05 2007-06-21 Toshitsu Kagaku Kenkyusho:Kk 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤
DE602007009995D1 (de) 2006-08-01 2010-12-02 Pieris Ag Muteine von tearlipocalin und verfahren zu deren gewinnung
WO2009037566A2 (en) 2007-06-19 2009-03-26 Uvarkina Tamara P Hyaluronidase and method of use thereof
CN101970650B (zh) 2008-03-06 2017-07-25 哈洛齐梅公司 可溶性透明质酸酶的大规模生产
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US20090311237A1 (en) 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
ES2543705T3 (es) 2009-06-26 2015-08-21 Novo Nordisk A/S Preparación que contiene insulina, nicotinamida y arginina
PT2477603E (pt) * 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
JP5136582B2 (ja) 2010-03-24 2013-02-06 ブラザー工業株式会社 現像カートリッジ
DK2595624T3 (en) 2010-07-20 2018-03-26 Halozyme Inc Methods of treating or preventing adverse side effects associated with administration of an anti-hyaluronan agent
US8401194B2 (en) * 2010-10-15 2013-03-19 Roche Diagnostics Operations, Inc. Diabetes care kit that is preconfigured to establish a secure bidirectional communication link between a blood glucose meter and insulin pump
EP2907504B1 (en) 2011-02-08 2017-06-28 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
US9149160B2 (en) 2011-03-17 2015-10-06 Evolution Technologies Inc. Bath chair
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US20130022592A1 (en) 2011-06-17 2013-01-24 Daniel Edward Vaughn Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
EP2720712B1 (en) 2011-06-17 2016-03-02 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US20130071394A1 (en) * 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
CA2853358A1 (en) 2011-10-24 2013-05-02 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
SG11201403714TA (en) 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
EP2833905B1 (en) 2012-04-04 2018-05-02 Halozyme, Inc. Combination therapy with hyaluronidase and a tumor-targeted taxane
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
EP3814191A1 (en) 2018-06-28 2021-05-05 Konux GmbH Planning of maintenance of railway
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
US10818036B1 (en) 2019-06-28 2020-10-27 GM Cruise Holdings, LLC Compensation in vehicle sensor calibration for sloped vehicle calibration environment
EP4033972A4 (en) 2019-12-02 2024-01-10 Binah.Ai Ltd SYSTEM AND METHOD FOR PHYSIOLOGICAL MEASUREMENTS FROM OPTICAL DATA

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009128917A2 (en) * 2008-04-14 2009-10-22 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
US20100143457A1 (en) * 2008-12-09 2010-06-10 Ge Wei Extended soluble PH20 polypeptides and uses thereof
WO2012136768A1 (en) * 2011-04-08 2012-10-11 Hans-Dieter Haubeck Use of mutants of human hyaluronidase ph-20 with increased chondroitinase activity for axonal regrowth

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A. V. MAKSIMENKO ; YU. V. SCHECHILINA ; E. G. TISCHENKO: "Resistance of Dextran-Modified Hyaluronidase to Inhibition by Heparin", BIOCHEMISTRY (MOSCOW), KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 66, no. 4, 1 April 2001 (2001-04-01), Ne, pages 456 - 463, XP019294336, ISSN: 1608-3040 *
ARMING SIGRID, STROBL B, WECHSELBERGER C, KREIL G: "In vitro mutagenesis of PH-20 hyaluronidase from human sperm", vol. 247, no. 3, 1 August 1997 (1997-08-01), pages 810 - 814, XP002661048 *
CAROLE E. SCHANT�, GUY ZUBER, CORINNE HERLIN, THIERRY F. VANDAMME: "Improvement of hyaluronic acid enzymatic stability by the grafting of amino-acids", CARBOHYDRATE POLYMERS, 1 October 2011 (2011-10-01), XP055058200, ISSN: 01448617, DOI: 10.1016/j.carbpol.2011.10.050 *
CSOKA A B, FROST G I, STERN R: "The six hyaluronidase-like genes in the human and mouse genomes.", MATRIX BIOLOGY, ELSEVIER, NL, vol. 20, no. 8, 1 December 2001 (2001-12-01), NL, pages 499 - 508, XP002507271, ISSN: 0945-053X, DOI: 10.1016/S0945-053X(01)00172-X *
JIANG PING; HOFER ANTHONY; HALLER MICHAEL; KELLER GILBERT A; BREKKEN CHRISTIAN; BOOKBINDER LOUIS H; FROST GREGORY I: "Effects of recombinant human PH20 (rHuPH20) on interstitial matrices: creating a favorable environment for the delivery of cytostatic agents", AMERICAN ASSOCIATION FOR CANCER RESEARCH. PROCEEDINGS OF THE ANNUAL MEETING, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 46, 1 April 2005 (2005-04-01), US, pages 1198, XP001525054, ISSN: 0197-016X *
S. REITINGER, J. MULLEGGER, B. GREIDERER, J. E. NIELSEN, G. LEPPERDINGER: "Designed Human Serum Hyaluronidase 1 Variant, HYAL1�L, Exhibits Activity up to pH 5.9", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 284, no. 29, 17 July 2009 (2009-07-17), pages 19173 - 19177, XP055058375, ISSN: 00219258, DOI: 10.1074/jbc.C109.004358 *
SEATON G J, HALL L, JONES R: "Rat sperm 2B1 glycoprotein (PH20) contains a C-terminal sequence motif for attachment of a glycosyl phosphatidylinositol anchor. Effects of endoproteolytic cleavage on hyaluronidase activity", BIOLOGY OF REPRODUCTION, NEW YORK, NY [U.A.] : ACADEM. PRESS, US, vol. 62, no. 6, 1 June 2000 (2000-06-01), US, pages 1667 - 1676, XP003006238, ISSN: 0006-3363, DOI: 10.1095/biolreprod62.6.1667 *

Also Published As

Publication number Publication date
ES2749620T3 (es) 2020-03-23
US12371685B2 (en) 2025-07-29
CN104244968A (zh) 2014-12-24
US12091692B2 (en) 2024-09-17
IL280949B (en) 2022-12-01
US12123035B2 (en) 2024-10-22
US12077791B2 (en) 2024-09-03
US20210277376A1 (en) 2021-09-09
WO2013102144A8 (en) 2013-08-29
US9447401B2 (en) 2016-09-20
IL274798A (en) 2020-07-30
AU2012362141A1 (en) 2014-07-10
US12060590B2 (en) 2024-08-13
US20140178330A9 (en) 2014-06-26
US20130302275A1 (en) 2013-11-14
MX361727B (es) 2018-12-14
US20230151346A1 (en) 2023-05-18
US20230287381A1 (en) 2023-09-14
NZ720075A (en) 2020-03-27
WO2013102144A3 (en) 2014-02-06
US10865400B2 (en) 2020-12-15
PT3130347T (pt) 2019-12-10
US11952600B2 (en) 2024-04-09
EA201400772A1 (ru) 2015-07-30
US20250197834A1 (en) 2025-06-19
IL274798B (en) 2021-03-25
EA030252B1 (ru) 2018-07-31
IL317266A (en) 2025-01-01
US12110520B2 (en) 2024-10-08
MX2014007966A (es) 2014-10-17
JP6422933B2 (ja) 2018-11-14
SG11201403714TA (en) 2014-07-30
WO2013102144A2 (en) 2013-07-04
SI3130347T1 (sl) 2020-02-28
US20240026328A1 (en) 2024-01-25
US20200255814A1 (en) 2020-08-13
US12195773B2 (en) 2025-01-14
CA2861919C (en) 2019-04-02
US11041149B2 (en) 2021-06-22
US20230250409A1 (en) 2023-08-10
US20240209337A1 (en) 2024-06-27
JP2017112999A (ja) 2017-06-29
US12104184B2 (en) 2024-10-01
AU2017245352B2 (en) 2019-08-01
US20240026327A1 (en) 2024-01-25
RS59703B1 (sr) 2020-01-31
DK2797622T3 (en) 2017-01-16
IL233192A0 (en) 2014-07-31
US20210284985A1 (en) 2021-09-16
PL3130347T3 (pl) 2020-04-30
US11066656B2 (en) 2021-07-20
US20240002826A1 (en) 2024-01-04
EP3130347B1 (en) 2019-09-18
AU2017245352A1 (en) 2017-11-02
US20230357739A1 (en) 2023-11-09
ES2609582T3 (es) 2017-04-21
US12037618B2 (en) 2024-07-16
AU2012362141B2 (en) 2017-09-21
US12054758B2 (en) 2024-08-06
LT3130347T (lt) 2019-10-25
US12104185B2 (en) 2024-10-01
US20200318091A1 (en) 2020-10-08
US12152262B2 (en) 2024-11-26
IL298330A (en) 2023-01-01
CY1122532T1 (el) 2021-01-27
CN104244968B (zh) 2017-07-25
DK3130347T3 (da) 2019-10-14
CA2861919A1 (en) 2013-07-04
US20240011008A1 (en) 2024-01-11
US20250154488A1 (en) 2025-05-15
US20250197832A1 (en) 2025-06-19
HK1202814A1 (zh) 2015-10-09
EP2797622A2 (en) 2014-11-05
JP6067746B2 (ja) 2017-01-25
US20250197835A1 (en) 2025-06-19
NZ626126A (en) 2016-06-24
US20230295592A1 (en) 2023-09-21
US20250197836A1 (en) 2025-06-19
IL298330B1 (en) 2025-03-01
US20230212547A1 (en) 2023-07-06
US20240002825A1 (en) 2024-01-04
US12049652B2 (en) 2024-07-30
US12600959B2 (en) 2026-04-14
IL233192B (en) 2020-06-30
US20260226445A1 (en) 2026-08-06
US12264345B1 (en) 2025-04-01
US20230295593A1 (en) 2023-09-21
US20160362670A1 (en) 2016-12-15
US20240318158A1 (en) 2024-09-26
SG10201604470TA (en) 2016-07-28
US20250197833A1 (en) 2025-06-19
EP3130347A1 (en) 2017-02-15
JP2015504666A (ja) 2015-02-16
US12018298B2 (en) 2024-06-25
MX2018012394A (es) 2020-09-02
HUE047849T2 (hu) 2020-05-28
BR112014016195A2 (pt) 2020-10-27
IL280949A (en) 2021-04-29
EP2797622B1 (en) 2016-10-12
IL280949B2 (en) 2023-04-01
US20250051747A1 (en) 2025-02-13
SMT201900630T1 (it) 2020-01-14
HRP20192249T1 (hr) 2020-03-06

Similar Documents

Publication Publication Date Title
EA201400772A1 (ru) Варианты полипептидов ph20, композиции на их основе и их применение
JO3357B1 (ar) مركبات إيميدازوبيروليدينون
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
EA201290103A1 (ru) Гетероциклические соединения и их использование
EA201492050A1 (ru) Модуляторы ядерного транспорта и их применение
MX389256B (es) Compuestos heterociclicos y usos de los mismos.
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
AU2012284088A8 (en) Heterocyclic compounds and uses thereof
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
PH12014500468A1 (en) Heterocyclic compounds and uses thereof
BR112013033098B8 (pt) inibidores de glicosidade seletivos e usos dos mesmos
MX2016008448A (es) Conjugados de var2csa-farmaco.
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
EA201490037A1 (ru) Антагонисты trpv4
GEP201706621B (en) Benzamides
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
BR112015005562A2 (pt) compostos de aminoisoquinolina, suas composições e uso dos novos compostos como inibidores da proteína quinase.
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
EA201492280A1 (ru) Стабильный состав пексиганана

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

TH4A Publication of the corrected specification to eurasian patent